Kleiman AA, García EJA

Language: Spanish
References: 16
Page: 421-426
PDF size: 922.84 Kb.

ABSTRACT

Organ transplants are a complex medical intervention that allows for the replacement of organs damaged due to chronic or traumatic diseases. This process includes donor selection, recipient evaluation, extraction, preservation, surgery, and post-operative care. Immunosuppressants are key to preventing acute or chronic rejection. However, despite medical advancements, the demand for organs exceeds the availability, with thousands of patients on waiting lists. Xenotransplants, such as porcine pancreatic islets, have emerged as a promising alternative, especially for treating type 1 diabetes and reducing insulin dependency. Additionally, genetic engineering has enabled the modification of pig organs to avoid immune rejection in humans, as seen with CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-edited kidneys. In summary, tissue engineering has also advanced, allowing the creation of functional organs from stem cells. These innovations offer hope to overcome the increasing organ demand and improve the quality of life for patients in need of a transplant.

REFERENCES

1. González-Pérez MK, Neri-Vela R, Quintero-Castañón R. El trasplantede córnea en México. Antecedentes históricos. Revista Mexicana deOftalmología. 2012; 86 (4): 187-190.

2. Langer R. Tissue engineering. Mol Ther. 2000; 1 (1): 12-15.

3. Careaga RG, Zetina THJ. Trasplante de órganos torácicos en México,Ed. El Manual Moderno. 2014.

4. Centro Nacional de Trasplantes (CENATRA). (2024). Estadísticasanuales 2024. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/967152/ESTADISTICAS_ANUAL_2024.pdf

5. Arrunátegui AM, Ramón DS, Viola LM, Olsen LG, Jaramillo A. Aspectostécnicos y clínicos de la prueba cruzada de histocompatibilidad enel trasplante de órganos sólidos. Biomed. 2022; 42 (2): 391-413.

6. Chick WL, Like AA, Lauris V. Beta cell culture on synthetic capillaries:an artificial endocrine pancreas. Science. 1975; 187 (4179): 847-849.

7. Kobayashi H, Ikada Y, Moritera T, Ogura Y, Honda Y. Collagenimmobilizedhydrogel as a material for lamellar keratoplasty. J ApplBiomater. 1991; 2 (4): 261-267.

8. Narushima M, Kobayashi N, Okitsu T, Tanaka Y, Li SA, Chen Y et al.A human beta-cell line for transplantation therapy to control type 1diabetes. Nat Biotechnol. 2005; 23 (10): 1274-1282.

9. Sullivan SJ, Maki T, Borland KM, Mahoney MD, Solomon BA, MullerTE et al. Biohybrid artificial pancreas: long-term implantation studiesin diabetic, pancreatectomized dogs. Science. 1991; 252 (5006):718-721.

10. Griffith BP, Goerlich CE, Singh AK, Rothblatt M, Lau CL, Shah A et al.Genetically modified porcine-to-human cardiac xenotransplantation.N Engl J Med. 2022; 387 (1): 35-44.

11. Cooper DKC, Riella LV, Kawai T, Fishman JA, Williams WW, Elias Net al. The time has come: the case for initiating pilot clinical trials ofpig kidney xenotransplantation. Ann Surg. 2024; 281 (2): 204-209.

12. Griffith LG, Naughton G. Tissue engineering--current challenges andexpanding opportunities. Science. 2002; 295 (5557): 1009-1014.

13. Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G etal. Repopulation of mouse liver with human hepatocytes and in vivoinfection with hepatitis B virus. Hepatology. 2001; 33 (4): 981-988.

14. Wang Y, Zheng Q, Sun Z, Wang C, Cen J, Zhang X et al. Reversal ofliver failure using a bioartificial liver device implanted with clinicalgradehuman-induced hepatocytes. Cell Stem Cell. 2023; 30 (5):617-631.e8.

15. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, KahakuE, Eguchi S et al. Clinical experience with a bioartificial liver in thetreatment of severe liver failure. A phase I clinical trial. Ann Surg.1997; 225 (5): 484-491; discussion 491-494.

16. Wang J, Xie W, Li N, Li W, Zhang Z, Fan N et al. Generation of ahumanized mesonephros in pigs from induced pluripotent stem cellsvia embryo complementation. Cell Stem Cell. 2023; 30 (9): 1235-1245.e6.